Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
127,940,509
-
Number of holders
-
119
-
Total 13F shares, excl. options
-
80,524,601
-
Shares change
-
+1,674,104
-
Total reported value, excl. options
-
$540,295,292
-
Value change
-
+$11,110,651
-
Put/Call ratio
-
236%
-
Number of buys
-
64
-
Number of sells
-
38
-
Price
-
$6.71
Institutional Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q1 2024
As of 31 Mar 2024 Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) had 119 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 80,524,601 shares of stock of the company.
Largest 10 holders included BlackRock Inc., BROWN CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, RA CAPITAL MANAGEMENT, L.P., HHLR ADVISORS, LTD., STATE STREET CORP, NEW YORK STATE COMMON RETIREMENT FUND, GEODE CAPITAL MANAGEMENT, LLC, DIMENSIONAL FUND ADVISORS LP, and WELLINGTON MANAGEMENT GROUP LLP.
This table shows 119 institutional shareholders of the security as of 31 Mar 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.